{"id":68443,"date":"2026-06-17T22:30:02","date_gmt":"2026-06-17T14:30:02","guid":{"rendered":"https:\/\/flcube.com\/?p=68443"},"modified":"2026-06-17T22:30:03","modified_gmt":"2026-06-17T14:30:03","slug":"wuxi-xdc-partners-with-biodlink-international-for-monoclonal-antibody-intermediate-manufacturing-in-rmb-190-million-crdmo-agreement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68443","title":{"rendered":"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>WuXi XDC<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2268:HKG\">HKG: 2268<\/a>), a leading global end-to-end <strong>CRDMO<\/strong> (Contract Research, Development and Manufacturing Organization), announced a strategic partnership with fellow Hong Kong-listed company <strong>BioDlink International Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1875:HKG\">HKG: 1875<\/a>). Under the agreement, BioDlink will provide comprehensive <strong>process development and manufacturing services<\/strong> for <strong>monoclonal antibody (mAb) intermediate production<\/strong>, with total contract value of <strong>RMB 190 million<\/strong> (USD 28.1 million).<\/p>\n\n\n\n<h2 id=\"h-partnership-framework-overview\" class=\"wp-block-heading\">Partnership Framework Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>CRDMO Partner<\/strong><\/td><td>WuXi XDC (HKG: 2268)<\/td><\/tr><tr><td><strong>Service Provider<\/strong><\/td><td>BioDlink International Company Limited (HKG: 1875)<\/td><\/tr><tr><td><strong>Contract Type<\/strong><\/td><td>Process development and manufacturing services<\/td><\/tr><tr><td><strong>Product Focus<\/strong><\/td><td>Monoclonal antibody (mAb) intermediates and biological samples<\/td><\/tr><tr><td><strong>Total Contract Value<\/strong><\/td><td>RMB 190 million (USD 28.1 million)<\/td><\/tr><tr><td><strong>Pricing Structure<\/strong><\/td><td>RMB 1.9 million (USD 281,188) per batch<\/td><\/tr><tr><td><strong>Contract Duration<\/strong><\/td><td>Effective upon signing through December 31, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-service-scope-amp-technical-capabilities\" class=\"wp-block-heading\">Service Scope &amp; Technical Capabilities<\/h2>\n\n\n\n<h3 id=\"h-comprehensive-mab-intermediate-production-services\" class=\"wp-block-heading\">Comprehensive mAb Intermediate Production Services<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cell Line Operations:<\/strong> Cell thawing and cell passaging<\/li>\n\n\n\n<li><strong>Upstream Processing:<\/strong> N-stage cell culture operations<\/li>\n\n\n\n<li><strong>Downstream Processing:<\/strong> Protein purification and formulation<\/li>\n\n\n\n<li><strong>Final Preparation:<\/strong> Excipient addition and intermediate preparation<\/li>\n\n\n\n<li><strong>Quality Assurance:<\/strong> Full suite of analytical and quality control services for biological samples<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-integration-benefits\" class=\"wp-block-heading\">Strategic Integration Benefits<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capacity Optimization:<\/strong> Enables WuXi XDC to leverage specialized manufacturing capacity<\/li>\n\n\n\n<li><strong>Technical Specialization:<\/strong> Access to BioDlink&#8217;s expertise in mAb intermediate production<\/li>\n\n\n\n<li><strong>Supply Chain Resilience:<\/strong> Diversified manufacturing network for critical biologics intermediates<\/li>\n\n\n\n<li><strong>Scalability:<\/strong> Flexible batch-based pricing supports variable production requirements<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-industry-implications\" class=\"wp-block-heading\">Market Impact &amp; Industry Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CRDMO Ecosystem Growth:<\/strong> Demonstrates maturing Chinese biopharmaceutical contract manufacturing landscape<\/li>\n\n\n\n<li><strong>Domestic Partnership Model:<\/strong> Two Hong Kong-listed Chinese companies collaborating on advanced biologics manufacturing<\/li>\n\n\n\n<li><strong>Financial Scale:<\/strong> RMB 190 million contract represents significant commercial validation for both parties<\/li>\n\n\n\n<li><strong>Capacity Utilization:<\/strong> Supports efficient use of specialized biomanufacturing infrastructure in China<\/li>\n\n\n\n<li><strong>Global Competitiveness:<\/strong> Strengthens China&#8217;s position as integrated biologics manufacturing hub<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-business-outlook\" class=\"wp-block-heading\">Strategic Rationale &amp; Business Outlook<\/h2>\n\n\n\n<h3 id=\"h-for-wuxi-xdc\" class=\"wp-block-heading\">For WuXi XDC<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capacity Flexibility:<\/strong> Supplements internal manufacturing capabilities with external specialized capacity<\/li>\n\n\n\n<li><strong>Client Service Enhancement:<\/strong> Ensures reliable supply chain for monoclonal antibody programs<\/li>\n\n\n\n<li><strong>Cost Optimization:<\/strong> Batch-based pricing provides predictable cost structure for intermediate production<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-biodlink-international\" class=\"wp-block-heading\">For BioDlink International<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Diversification:<\/strong> Secures substantial near-term revenue stream through year-end 2026<\/li>\n\n\n\n<li><strong>Capability Validation:<\/strong> Partnership with industry leader validates technical and quality standards<\/li>\n\n\n\n<li><strong>Market Positioning:<\/strong> Establishes BioDlink as credible partner in high-value mAb intermediate manufacturing<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This partnership exemplifies the evolving sophistication of China&#8217;s biopharmaceutical manufacturing ecosystem, where specialized service providers collaborate to deliver integrated solutions for complex biologics development. The substantial contract value and comprehensive service scope demonstrate both companies&#8217; commitment to building world-class CRDMO capabilities that can compete globally. By combining WuXi XDC&#8217;s end-to-end platform with BioDlink&#8217;s specialized intermediate manufacturing expertise, the partnership creates a robust supply chain solution that supports the growing demand for monoclonal antibody therapeutics from both domestic and international clients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding business partnerships, revenue expectations, and market positioning. Actual results may differ due to contract execution, operational performance, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061700020_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061700020_c.\"><\/object><a id=\"wp-block-file--media-35d7863c-bea5-4a17-8169-db5d016a1850\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061700020_c.pdf\">2026061700020_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061700020_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-35d7863c-bea5-4a17-8169-db5d016a1850\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WuXi XDC (HKG: 2268), a leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4808,19,1894,1183,364],"class_list":["post-68443","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biodlink","tag-cro-cmo-cdmo","tag-hkg-1875","tag-hkg-2268","tag-wuxi-xdc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi XDC (HKG: 2268), a leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization), announced a strategic partnership with fellow Hong Kong-listed company BioDlink International Company Limited (HKG: 1875). Under the agreement, BioDlink will provide comprehensive process development and manufacturing services for monoclonal antibody (mAb) intermediate production, with total contract value of RMB 190 million (USD 28.1 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68443\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement\" \/>\n<meta property=\"og:description\" content=\"WuXi XDC (HKG: 2268), a leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization), announced a strategic partnership with fellow Hong Kong-listed company BioDlink International Company Limited (HKG: 1875). Under the agreement, BioDlink will provide comprehensive process development and manufacturing services for monoclonal antibody (mAb) intermediate production, with total contract value of RMB 190 million (USD 28.1 million).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68443\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-17T14:30:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-17T14:30:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68443#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68443\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement\",\"datePublished\":\"2026-06-17T14:30:02+00:00\",\"dateModified\":\"2026-06-17T14:30:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68443\"},\"wordCount\":476,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BioDlink\",\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 1875\",\"HKG: 2268\",\"WuXi XDC\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68443#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68443\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68443\",\"name\":\"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-17T14:30:02+00:00\",\"dateModified\":\"2026-06-17T14:30:03+00:00\",\"description\":\"WuXi XDC (HKG: 2268), a leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization), announced a strategic partnership with fellow Hong Kong-listed company BioDlink International Company Limited (HKG: 1875). Under the agreement, BioDlink will provide comprehensive process development and manufacturing services for monoclonal antibody (mAb) intermediate production, with total contract value of RMB 190 million (USD 28.1 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68443#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68443\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68443#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement - Insight, China&#039;s Pharmaceutical Industry","description":"WuXi XDC (HKG: 2268), a leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization), announced a strategic partnership with fellow Hong Kong-listed company BioDlink International Company Limited (HKG: 1875). Under the agreement, BioDlink will provide comprehensive process development and manufacturing services for monoclonal antibody (mAb) intermediate production, with total contract value of RMB 190 million (USD 28.1 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68443","og_locale":"en_US","og_type":"article","og_title":"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement","og_description":"WuXi XDC (HKG: 2268), a leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization), announced a strategic partnership with fellow Hong Kong-listed company BioDlink International Company Limited (HKG: 1875). Under the agreement, BioDlink will provide comprehensive process development and manufacturing services for monoclonal antibody (mAb) intermediate production, with total contract value of RMB 190 million (USD 28.1 million).","og_url":"https:\/\/flcube.com\/?p=68443","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-17T14:30:02+00:00","article_modified_time":"2026-06-17T14:30:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68443#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68443"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement","datePublished":"2026-06-17T14:30:02+00:00","dateModified":"2026-06-17T14:30:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68443"},"wordCount":476,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BioDlink","CRO \/ CMO \/ CDMO","HKG: 1875","HKG: 2268","WuXi XDC"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68443#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68443","url":"https:\/\/flcube.com\/?p=68443","name":"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-17T14:30:02+00:00","dateModified":"2026-06-17T14:30:03+00:00","description":"WuXi XDC (HKG: 2268), a leading global end-to-end CRDMO (Contract Research, Development and Manufacturing Organization), announced a strategic partnership with fellow Hong Kong-listed company BioDlink International Company Limited (HKG: 1875). Under the agreement, BioDlink will provide comprehensive process development and manufacturing services for monoclonal antibody (mAb) intermediate production, with total contract value of RMB 190 million (USD 28.1 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68443#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68443"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68443#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68443"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68443\/revisions"}],"predecessor-version":[{"id":68445,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68443\/revisions\/68445"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}